National Health (Originator Brand) Amendment Determination 2016 (No. 1) (PB 8 of 2016) (Cth)

PB 8 of 2016

National Health (Originator Brand) Amendment Determination 2016 (No. 1)

National Health Act 1953

I, DIANNA PROSSER, Assistant Secretary (Acting) , Pharmaceutical Policy Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated        28     January 2016

______________________________________

DIANNA PROSSER
Assistant Secretary (Acting)
Pharmaceutical Policy Branch
Pharmaceutical Benefits Division
Department of Health

1. Name of Determination

   (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2016 (No. 1).

   (2)     This Determination may also be cited as PB 8 of 2016.

2. Commencement

   This Determination commences on 1 February 2016.

3. Amendments to PB 100 of 2015

   Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]   Schedule 1 (after table item 16)

Insert:

16A Apomorphine Apomine

[2]   Schedule 1, table item 83 [entry for fentanyl]

Insert as first item, in the columns in the order indicated

Abstral Sublingual

[3]   Schedule 1 (after table item 246)

Insert:

246A Voriconazole Vfend